JP2010509331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509331A5 JP2010509331A5 JP2009536282A JP2009536282A JP2010509331A5 JP 2010509331 A5 JP2010509331 A5 JP 2010509331A5 JP 2009536282 A JP2009536282 A JP 2009536282A JP 2009536282 A JP2009536282 A JP 2009536282A JP 2010509331 A5 JP2010509331 A5 JP 2010509331A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- taxane
- vegf antibody
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123237 Taxane Drugs 0.000 claims description 47
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 45
- 239000002105 nanoparticle Substances 0.000 claims description 34
- 206010027476 Metastases Diseases 0.000 claims description 22
- 230000009401 metastasis Effects 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 102000014914 Carrier Proteins Human genes 0.000 claims description 13
- 108010078791 Carrier Proteins Proteins 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/594,417 | 2006-11-06 | ||
| US11/594,417 US20070166388A1 (en) | 2005-02-18 | 2006-11-06 | Combinations and modes of administration of therapeutic agents and combination therapy |
| PCT/US2007/023446 WO2008057562A1 (en) | 2006-11-06 | 2007-11-06 | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230872A Division JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509331A JP2010509331A (ja) | 2010-03-25 |
| JP2010509331A5 true JP2010509331A5 (enExample) | 2011-12-15 |
| JP5931323B2 JP5931323B2 (ja) | 2016-06-08 |
Family
ID=39111840
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536282A Active JP5931323B2 (ja) | 2006-11-06 | 2007-11-06 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2013230872A Withdrawn JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2015208557A Pending JP2016014073A (ja) | 2006-11-06 | 2015-10-23 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230872A Withdrawn JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2015208557A Pending JP2016014073A (ja) | 2006-11-06 | 2015-10-23 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20070166388A1 (enExample) |
| EP (3) | EP2097078B1 (enExample) |
| JP (3) | JP5931323B2 (enExample) |
| KR (4) | KR20150065957A (enExample) |
| CN (2) | CN101573108A (enExample) |
| AU (1) | AU2007317859B2 (enExample) |
| BR (1) | BRPI0718528A2 (enExample) |
| CA (1) | CA2668607A1 (enExample) |
| CY (2) | CY1115271T1 (enExample) |
| DK (2) | DK2481405T3 (enExample) |
| ES (2) | ES2469716T3 (enExample) |
| HU (1) | HUE028472T2 (enExample) |
| IL (2) | IL198576A (enExample) |
| MX (1) | MX2009004803A (enExample) |
| NO (1) | NO343908B1 (enExample) |
| NZ (1) | NZ576856A (enExample) |
| PL (2) | PL2097078T3 (enExample) |
| PT (2) | PT2097078E (enExample) |
| RU (2) | RU2009121568A (enExample) |
| SI (2) | SI2481405T1 (enExample) |
| WO (1) | WO2008057562A1 (enExample) |
| ZA (1) | ZA200903132B (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070116761A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| NZ502500A (en) * | 1997-06-27 | 2002-03-28 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| SI3248600T1 (sl) * | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP3527202A1 (en) * | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| PL1931321T3 (pl) | 2005-08-31 | 2019-08-30 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| US8440625B2 (en) * | 2006-06-26 | 2013-05-14 | University Of British Columbia | Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| KR20090095571A (ko) * | 2006-11-01 | 2009-09-09 | 조지 매이슨 인털렉춸 프로퍼티즈, 인코퍼레이티드 | 암을 검출하고 조절하기 위한 방법 |
| EP3470071A1 (en) * | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| LT2481402T (lt) * | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| CA2686736A1 (en) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
| WO2008150532A1 (en) * | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| AU2008269179A1 (en) * | 2007-06-22 | 2008-12-31 | Scidose Llc | Solubilized formulation of docetaxel without Tween 80 |
| ITMI20080284A1 (it) * | 2008-02-22 | 2009-08-23 | Indena Spa | Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono |
| CA2721153C (en) * | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| EP2310006A4 (en) | 2008-07-03 | 2012-04-25 | Mayo Foundation | CANCER TREATMENT |
| EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
| RU2555326C2 (ru) * | 2009-01-16 | 2015-07-10 | Риджел Фармасьютикалз, Инк. | ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА |
| JP5725563B2 (ja) * | 2009-03-13 | 2015-05-27 | アブラクシス バイオサイエンス， エルエルシー | チオコルヒチン誘導体との組み合わせ療法 |
| MX378130B (es) | 2009-04-15 | 2025-03-10 | Abraxis Bioscience Llc | Métodos y composiciones de nanopartículas sin priones. |
| MX2012000383A (es) * | 2009-07-07 | 2012-06-01 | Normoxys Inc | Método para reducir la resistencia a terapias multidroga utilizando tripirofosfato de inositol. |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| CN103237810A (zh) * | 2010-02-23 | 2013-08-07 | 霍夫曼-拉罗奇有限公司 | 用于治疗卵巢癌的抗血管发生疗法 |
| PT2552438T (pt) | 2010-03-26 | 2016-07-07 | Abraxis Bioscience Llc | Métodos de tratamento de carcinoma hepatocelular |
| EP3141245A1 (en) * | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| AU2011264590B2 (en) * | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| US20120121510A1 (en) * | 2010-11-11 | 2012-05-17 | Brem Rachel F | Localized therapy following breast cancer surgery |
| WO2012068098A1 (en) * | 2010-11-15 | 2012-05-24 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| LT2707030T (lt) | 2011-05-09 | 2020-07-10 | Mayo Foundation For Medical Education And Research | Vėžio gydymas |
| AU2012318239B2 (en) | 2011-11-01 | 2015-07-09 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
| EP3553083A1 (en) * | 2012-03-13 | 2019-10-16 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of ovarian cancer |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| MX377729B (es) * | 2013-02-11 | 2025-03-11 | Abraxis Bioscience Llc | Métodos para tratamiento del melanoma. |
| US10744110B2 (en) | 2013-03-12 | 2020-08-18 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
| WO2015134543A1 (en) * | 2014-03-05 | 2015-09-11 | Sorrento Therapeutics, Inc. | Pharmacokinetically equivalent nanoparticle compositions |
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| US20160250351A1 (en) | 2014-06-13 | 2016-09-01 | Mayo Foundation For Medical Education And Research | Treating Lymphomas |
| AU2015277494A1 (en) | 2014-06-16 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US20150359810A1 (en) | 2014-06-17 | 2015-12-17 | Celgene Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| CN104434808A (zh) * | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种治疗性纳米粒子及其制备方法 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| EP3204413B1 (en) * | 2014-10-06 | 2019-08-28 | Mayo Foundation for Medical Education and Research | Carrier-antibody compositions and methods of making and using the same |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| KR102606071B1 (ko) | 2015-06-29 | 2023-11-27 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| CN114796130B (zh) * | 2015-08-18 | 2023-10-20 | 梅约医学教育与研究基金会 | 载体结合剂组合物及其制备和使用方法 |
| WO2017176265A1 (en) * | 2016-04-06 | 2017-10-12 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| CN105288639A (zh) * | 2015-11-23 | 2016-02-03 | 中国药科大学 | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| WO2017139698A1 (en) * | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| RU2019105550A (ru) * | 2016-08-05 | 2020-09-07 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования |
| TWI771315B (zh) * | 2016-08-26 | 2022-07-21 | 奧野哲治 | 微小奈米化藥劑及其利用 |
| KR20220151022A (ko) | 2016-09-01 | 2022-11-11 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| CA3035377A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Nanoparticle compositions for targeting t-cell cancers |
| EP3510048A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Methods of treating pd-l1 expressing cancer |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| EP3509643A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| CN106310291A (zh) * | 2016-09-14 | 2017-01-11 | 东南大学 | 主动靶向抗肿瘤纳米药物及其制备方法和应用 |
| PT3532059T (pt) | 2016-10-27 | 2022-03-02 | Celgene Quanticel Res Inc | Terapêutica de combinação de inibidores de proteínas de bromodomínio e domínio extraterminal |
| EP3532077A4 (en) * | 2016-10-28 | 2020-06-10 | Nant Holdings IP, LLC | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death |
| CN111918652A (zh) | 2017-11-06 | 2020-11-10 | 拉普特医疗公司 | 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂 |
| WO2019104042A1 (en) * | 2017-11-21 | 2019-05-31 | University Of Iowa Research Foundation | Synthetically lethal nanoparticles for treatment of cancers |
| MX2020006042A (es) * | 2017-12-19 | 2020-10-20 | Abraxis Bioscience Llc | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. |
| JP7517988B2 (ja) | 2018-01-26 | 2024-07-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗ｖｅｇｆ剤を使用した血管新生障害の治療のための方法および組成物 |
| KR102837015B1 (ko) | 2018-03-20 | 2025-07-23 | 아브락시스 바이오사이언스, 엘엘씨 | mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법 |
| CA3158764A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| KR102263606B1 (ko) | 2020-02-11 | 2021-06-10 | 충북대학교 산학협력단 | 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| CZ283717B6 (cs) | 1991-03-06 | 1998-06-17 | MERCK Patent Gesellschaft mit beschränkter Haftung | Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| AU1831395A (en) | 1994-01-14 | 1995-08-01 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| HUP0102048A3 (en) | 1998-04-16 | 2002-12-28 | Eurovita As | Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga and their use |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| KR20150008458A (ko) * | 2003-05-30 | 2015-01-22 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체를 사용한 치료 |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| MXPA06003163A (es) * | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
| WO2006001911A2 (en) | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor beta chain and methods of use |
| CN114053429A (zh) | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| CN106075435A (zh) | 2004-06-04 | 2016-11-09 | 健泰科生物技术公司 | 用于治疗多发性硬化的方法 |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| MX2007008810A (es) * | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| SI3248600T1 (sl) * | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| CN101232901B (zh) | 2005-02-28 | 2011-12-07 | 卫材R&D管理有限公司 | 磺酰胺化合物和血管生成抑制物质的联合新应用 |
| PL1931321T3 (pl) * | 2005-08-31 | 2019-08-30 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| EP3527202A1 (en) * | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
-
2006
- 2006-11-06 US US11/594,417 patent/US20070166388A1/en not_active Abandoned
-
2007
- 2007-11-06 EP EP07839976.3A patent/EP2097078B1/en active Active
- 2007-11-06 KR KR1020157014446A patent/KR20150065957A/ko not_active Ceased
- 2007-11-06 MX MX2009004803A patent/MX2009004803A/es active IP Right Grant
- 2007-11-06 SI SI200731795A patent/SI2481405T1/sl unknown
- 2007-11-06 WO PCT/US2007/023446 patent/WO2008057562A1/en not_active Ceased
- 2007-11-06 ES ES07839976.3T patent/ES2469716T3/es active Active
- 2007-11-06 PT PT78399763T patent/PT2097078E/pt unknown
- 2007-11-06 PL PL07839976T patent/PL2097078T3/pl unknown
- 2007-11-06 RU RU2009121568/15A patent/RU2009121568A/ru unknown
- 2007-11-06 DK DK12154995.0T patent/DK2481405T3/en active
- 2007-11-06 ES ES12154995.0T patent/ES2576289T3/es active Active
- 2007-11-06 EP EP16161396.3A patent/EP3108885A1/en not_active Withdrawn
- 2007-11-06 PT PT121549950T patent/PT2481405E/pt unknown
- 2007-11-06 KR KR1020177002657A patent/KR101857142B1/ko active Active
- 2007-11-06 NZ NZ576856A patent/NZ576856A/en not_active Application Discontinuation
- 2007-11-06 AU AU2007317859A patent/AU2007317859B2/en active Active
- 2007-11-06 BR BRPI0718528-6A patent/BRPI0718528A2/pt not_active Application Discontinuation
- 2007-11-06 SI SI200731475T patent/SI2097078T1/sl unknown
- 2007-11-06 ZA ZA200903132A patent/ZA200903132B/xx unknown
- 2007-11-06 JP JP2009536282A patent/JP5931323B2/ja active Active
- 2007-11-06 EP EP12154995.0A patent/EP2481405B1/en active Active
- 2007-11-06 CN CNA2007800490545A patent/CN101573108A/zh active Pending
- 2007-11-06 PL PL12154995.0T patent/PL2481405T3/pl unknown
- 2007-11-06 CA CA002668607A patent/CA2668607A1/en not_active Abandoned
- 2007-11-06 DK DK07839976.3T patent/DK2097078T3/da active
- 2007-11-06 KR KR1020097011640A patent/KR20090087906A/ko not_active Ceased
- 2007-11-06 HU HUE12154995A patent/HUE028472T2/en unknown
- 2007-11-06 CN CN201510264733.0A patent/CN104940929A/zh active Pending
- 2007-11-06 KR KR1020187002044A patent/KR20180012339A/ko not_active Withdrawn
-
2009
- 2009-05-05 IL IL198576A patent/IL198576A/en active IP Right Grant
- 2009-06-05 NO NO20092179A patent/NO343908B1/no unknown
-
2013
- 2013-11-05 RU RU2013149282A patent/RU2673805C2/ru active
- 2013-11-07 JP JP2013230872A patent/JP2014043454A/ja not_active Withdrawn
-
2014
- 2014-06-26 CY CY20141100462T patent/CY1115271T1/el unknown
-
2015
- 2015-10-23 JP JP2015208557A patent/JP2016014073A/ja active Pending
-
2016
- 2016-03-02 IL IL244390A patent/IL244390A/en active IP Right Grant
- 2016-06-17 CY CY20161100552T patent/CY1117725T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509331A5 (enExample) | ||
| RU2009121568A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| JP2010529025A5 (enExample) | ||
| Agnello et al. | Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors | |
| JP2013503174A5 (enExample) | ||
| Yan et al. | Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo | |
| RU2021128415A (ru) | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения | |
| JP2016506908A5 (enExample) | ||
| JP2013527232A5 (enExample) | ||
| JP2013523656A5 (enExample) | ||
| JP2013527233A5 (enExample) | ||
| US12391944B2 (en) | Magnetic inorganic iron-based nanoparticles | |
| JP2017025090A5 (enExample) | ||
| JP2016513075A5 (enExample) | ||
| JP2016505018A5 (enExample) | ||
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| JP2016513657A5 (enExample) | ||
| Erdoğar et al. | Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer | |
| JP2013520442A5 (enExample) | ||
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2012158602A5 (enExample) | ||
| EP2481402A3 (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| JP2010523696A5 (enExample) | ||
| JP2015517529A5 (enExample) | ||
| WO2013173542A4 (en) | Methods for treating cancer with notch2/3 antibodies |